$17.74
1.86%
Downside
Day's Volatility :3.39%
Upside
1.55%
68.25%
Downside
52 Weeks Volatility :78.62%
Upside
32.68%
Period | Newamsterdam Pharma Company Nv | Index (Russel 2000) |
---|---|---|
3 Months | -11.3% | 0.0% |
6 Months | -6.39% | 0.0% |
1 Year | 128.9% | 0.0% |
3 Years | 71.4% | -20.8% |
Market Capitalization | 1.6B |
Book Value | $4.3 |
Earnings Per Share (EPS) | -2.62 |
Wall Street Target Price | 37.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -2306.93% |
Return On Assets TTM | -27.15% |
Return On Equity TTM | -54.08% |
Revenue TTM | 7.4M |
Revenue Per Share TTM | 0.09 |
Quarterly Revenue Growth YOY | 32.7% |
Gross Profit TTM | 0.0 |
EBITDA | -208.6M |
Diluted Eps TTM | -2.62 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.44 |
EPS Estimate Next Year | -1.74 |
EPS Estimate Current Quarter | -0.58 |
EPS Estimate Next Quarter | -0.51 |
What analysts predicted
Upside of 108.57%
Sell
Neutral
Buy
Newamsterdam Pharma Company Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Newamsterdam Pharma Company Nv | 5.09% | -6.39% | 128.9% | 71.4% | 71.4% |
Regeneron Pharmaceuticals, Inc. | -12.19% | 6.5% | 20.85% | 84.03% | 245.65% |
Novo Nordisk A/s | -11.15% | -6.13% | 27.31% | 138.21% | 354.53% |
Alnylam Pharmaceuticals, Inc. | 5.38% | 73.95% | 61.12% | 32.59% | 252.19% |
Vertex Pharmaceuticals Incorporated | -2.58% | 13.46% | 29.21% | 155.56% | 172.0% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Newamsterdam Pharma Company Nv | 30.14 | NA | NA | -2.44 | -0.54 | -0.27 | NA | 4.3 |
Regeneron Pharmaceuticals, Inc. | 26.37 | 26.37 | 1.36 | 45.03 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.54 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Newamsterdam Pharma Company Nv | Buy | $1.6B | 71.4% | 30.14 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $109.8B | 245.65% | 26.37 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 354.53% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.2B | 252.19% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $115.8B | 172.0% | 32.84 | -4.74% |
Insights on Newamsterdam Pharma Company Nv
Revenue is up for the last 2 quarters, 1.29M → 2.12M (in $), with an average increase of 39.0% per quarter
Netprofit is up for the last 2 quarters, -86.89M → -36.41M (in $), with an average increase of 138.6% per quarter
FCPM III SERVICES BV
Bain Capital Life Sciences Investors, LLC
RA Capital Management, LLC
Viking Global Investors LP
Medicxi Ventures Management (Jersey) Ltd
Cormorant Asset Management, LLC
Organization | Newamsterdam Pharma Company Nv |
Employees | 57 |
CEO | Dr. Michael Harvey Davidson FACC, Facp., M.D. |
Industry | Miscellaneous |
Virios Therapeutics Inc
$17.74
-0.06%
Lg Qraft Ai-powered Us Large Cap Core Etf
$17.74
-0.06%
Spdr Ftse International Gove
$17.74
-0.06%
John Hancock Investors Closed Fund
$17.74
-0.06%
Proshares Ultra High Yield
$17.74
-0.06%
Lichen China Ltd
$17.74
-0.06%
Arbutus Biopharma Corporation
$17.74
-0.06%
Eaton Vance Enh Eqt Inc Ii
$17.74
-0.06%
Western Asset Diversified Income Fund
$17.74
-0.06%